Table 2:

Sphingolipid levels in RBCs of control (n = 11) and untreated GD (n = 16) subjects, from the Dupuis et al. (13, 17) cohort (quantification method: Chipeaux et al. (20)). Values are in nmol/L of whole blood.

Group	GL-1	Lyso-GL1	Sph	S1P
CTR	120.25	5.44	1.63	1,053.94
CTR	57.67	5.20	0.95	1,164.57
CTR	54.93	5.98	4.00	1,330.29
CTR	69.00	4.84	2.21	935.63
CTR	68.02	5.82	4.57	1,473.63
CTR	82.36	4.92	4.09	1,337.20
CTR	82.94	5.80	4.00	1,629.01
CTR	131.19	5.21	1.17	1,563.42
CTR	93.34	5.05	5.01	1,098.66
CTR	83.55	5.15	4.70	1,149.52
CTR	90.56	5.46	4.72	1,274.03
GD	146.10	64.95	8.92	2,583.61
GD	97.17	54.93	11.02	2,817.87
GD	108.42	82.60	8.31	2,639.82
GD	171.37	39.77	10.64	2,165.20
GD	147.14	86.98	10.21	2,640.05
GD	116.03	70.86	10.21	3,032.91
GD	204.45	78.52	10.15	3,016.05
GD	85.88	51.49	6.66	2,214.62
GD	63.24	184.45	12.53	3,041.77
GD	184.08	59.42	10.27	2,984.12
GD	64.56	90.35	13.28	4,071.77
GD	108.19	164.93	16.84	2,885.60
GD	153.98	87.84	21.15	2,942.90
GD	121.87	64.69	8.44	2,503.87
GD	113.70	65.42	8.50	2,443.43
GD	163.92	38.85	16.31	1,861.51
Controls (mean ± SD)	84.89 ± 23.84	5.35 ± 0.38	3.37 ± 1.55	1,273.63 ± 218.62
GD patients (mean ± SD)	128.13 ± 41.34	80.38 ± 40.23	11.46 ± 3.79	2,740.32 ± 498.07